Clinical Trial News Archive
Get news By email or subscribe to our .
June 2007
June 4
AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results
for Anti-Cancer Compound Perifosine at ASCO Meeting
SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in
Phase 2 Malignant Melanoma Trial
MabThera Significantly Extends Survival And Cures More Patients
With Aggressive Lymphoma Than Chemotherapy Alone
Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II
trial of Cloretazine (VNP40101M) in Patients with Relapsed or
Refractory Small Cell Lung Cancer
Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in
Phase 2 Trial
Promising Results with Epratuzumab and Chemotherapy in Children
with Acute Lymphoblastic Leukemia
GenVec Announces Update of Safety and Efficacy Data from Pivotal
Phase II/III PACT Study of TNFerade at ASCO
New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting
Cougar Biotechnology Announces Presentation of Positive CB7630
Clinical Data at ASCO Annual Meeting
Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data
on Molecular Imaging Pharmaceutical for Prostate Cancer
Nexavar Significantly Extends Overall Survival by 44% in Liver
Cancer Patients
Investigational Cancer Drug Pertuzumab Shows Promising Results in
Advanced Breast Cancer When Combined with Herceptin
ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial
in B-Cell Chronic Lymphocytic Leukemia
Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90
Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory
Breast and Ovarian Cancers at ASCO
Kosan Presents Phase 1 Data Showing Promising Antitumor Activity
and Safety Profile of Epothilone KOS-1584 at ASCO
Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data
at Society Of Nuclear Medicine 2007 Annual Meeting
Phase 2 Clinical Results of Ganite Plus Standard Therapy in
Patients with Relapsed/Refractory Lymphoma Presented at ASCO
Cardiome And Astellas Announce Positive Results From ACT 2 Trial
Biothera's Imprime PGG Enhanced Effectiveness of Avastin in Cancer
Study
Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing
Promising Antitumor Activity in Multiple Myeloma at ASCO
Access and Somanta Announce Data to be Presented on Angiolix at
ASCO Oncology Conference
Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity
of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
Diatos Announces Positive Clinical Results for its DTS-201
Doxorubicin Prodrug Program
Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer
Patients Treated with Therapy Based on Ratiometric Dosing
New Data Show Pfizer's Axitinib Prolonged Overall Survival in
Advanced Pancreatic Cancer When Combined with Standard of Care
Chemotherapy
Newly Published Data Demonstrates Superiority of Cipralex Over
Duloxetine for Acute Treatment of Depression
Updated Overall Survival Data From Pivotal Herceptin Adjuvant
Studies in HER2-Positive Breast Cancer
Evotec Reports Positive Proof-of-Concept Top-Line Results with
Insomnia Drug Candidate EVT 201
Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and
Effective in Colorectal Cancer with Liver Metastases
Soliris Effective in PNH Patients With History of Aplastic Anemia
and Myelodysplastic Syndromes
Adding Thalidomide to Standard Therapy Improves Survival in Newly
Diagnosed Multiple Myeloma Patients Over Age 75
Positive Results for Second-Generation Taxus Liberte Coronary Stent
System Highlighted in Journal of American College of Cardiology
The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved
Progression Free Survival When Given Before and After Surgery in
Patients With Resectable Liver Metastases From Colorectal Cancer
Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New
Treatment Benchmark in Patients With Metastatic Colorectal Cancer
Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival
Compared to Chemotherapy Alone for Sarcoma Cancer Patients
Additional New Data from Satraplatin SPARC Phase 3 Investigational
Trial Presented at ASCO Annual Meeting
Additional New Data from Satraplatin SPARC Phase 3 Investigational
Trial Presented at ASCO Annual Meeting
New Study Suggests Better Patient Outcomes with CYPHER
Sirolimus-Eluting Coronary Stent than with Taxus Stent in
Real-World Clinical Settings
Genmab's HuMax-EGFr Shows Broad Potential in Cancer Treatment
Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of
GVAX Immunotherapy for Pancreatic Cancer
Dasatinib Shows High Early Response Rate as First Treatment for
Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
ChemGenex Reports Successful Personalized Dosing of Quinamed at
ASCO
Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line
Results with ...
Phase 2 Clinical Results of Ganite Plus Standard Therapy in
Patients with Relapsed/Refractory Lymphoma Presented at ASCO
Hana Biosciences Presents Data On Two Programs At the American
Society of Clinical Oncology Annual Meeting
Cipralex demonstrates superiority to duloxetine for acute treatment
of depression in new study
Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an
Important Treatment Option for Patients With Metastatic Colorectal
Cancer
Merck at ASCO 2007: Encouraging Results in Progression-Free
Survival in Patients With Aggressive Brain Tumors (glioblastoma)
Using Cilengitide in Phase I/IIa Study
Investigational Drug Cediranib (AZD2171) Shows Promise in Patients
With Recurrent Glioblastoma (GBM)
Introgen Reports Updated Phase 2 Advexin Data Correlating Improved
Survival, Tumor Responses and Predictive p53 Biomarker
Pharmexa A/S (DK) - Long lasting immune response and survival to
RAS vaccine
Hemispherx Presents Evidence of Ampligen Synergies with Existing
Antivirals at International Avian Influenza Conference
News from the Battlefield of Metastatic Cancer: Epeius
Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G)
from the Stone of Chemistry and Physics
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard
of Care in Second Line Treatment of Small Cell Lung Cancer - Jun 4, 2007
Vision Deficit in Retinitis Pigmentosa Mice Corrected with DNA
Nanoparticles
Study Shows Velcade Plus Doxil Improves Survival in Previously
Treated Patients With Multiple Myeloma
GSK'S Pazopanib Shows Positive Results in Patients with Advanced
Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
8-Year Long-term Data Demonstrate Prolonged Overall Survival and
Length of Disease Remission with Bexxar
Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in
Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
New Data on Market-Leading Velcade (Bortezomib) for Injection
Further Strengthen Role in Previously Treated Multiple Myeloma